



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/712,423	11/13/2003	Hamdi K. Hamdi	HAMD1-001B	9959

7590 01/29/2007
Matthew A. Newboles
STETINA BRUNDA GARRED & BRUCKER
75 Enterprise, Suite 250
Aliso Viejo, CA 92656

EXAMINER

GEMBEH, SHIRLEY V

ART UNIT	PAPER NUMBER
----------	--------------

1614

SHORTENED STATUTORY PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE
3 MONTHS	01/29/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

Office Action Summary

Application No.

10/712,423

Applicant(s)

HAMDI ET AL.

Examiner

Shirley V. Gembeh

Art Unit

1614

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 27 March 2006.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1,3, and 5-71 is/are pending in the application.
- 4a) Of the above claim(s) 12-14, 16 and 37-71 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1,3,5-11,15 and 17-36 is/are rejected.
- 7) ☒ Claim(s) 8,26-28 and 30 is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

The response filed 10/23/06 presents remarks and arguments to the office action mailed 6/20/06. Applicants' request for reconsideration of the rejection of claims in the last office action has been considered.

Applicants' arguments, filed, have been fully considered but they are not deemed to be persuasive. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Status of claims

Claims 1, 3, 5-11, 15 and 17-71 are pending.

Claims 37-71 are withdrawn from examining as to a non elected specie. Newly submitted claims 37-71 are directed to an invention that is independent or distinct from the invention originally claimed for the following reasons: The newly submitted claims are method for disrupting and preventing the reorganization of the cytoskeleton whereby an animal cell becomes globular is not the same and does not constitute the same mechanism as the method of treating. Disrupting the balance between critical cellular signals in a way that leads to cell death is a form that is totally different from treating and the search for one would not have lead to the search for the other The inventions are distinct if the (1) the inventions as claimed are either not capable of use together or

Art Unit: 1614

can have a materially different design, mode of operation, function, or effect; (2) the inventions do not overlap in scope, i.e., are mutually exclusive; and (3) the inventions as claimed are not obvious variants. See MPEP § 806.05(j). As already explained above.

Since applicant has received an action on the merits for the originally presented invention, this invention has been constructively elected by original presentation for prosecution on the merits. Accordingly, claims 37-71 are withdrawn from consideration as being directed to a non-elected invention. See 37 CFR 1.142(b) and MPEP § 821.03.

Claims 1, 3, 5-11, 15, and 17-36 are examined in this office action.

Affidavit

The affidavit statement submitted has been acknowledged and the response is based upon the consideration of the affidavit.

Claim Objections

Claims 8, 26-28 and 30 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.


Maintained Claim Rejections - 35 USC § 112-first paragraph

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Art Unit: 1614

I. Claims 1, 7 and 11 together with dependent claims 5, 9-10, 17-25, 29, 31 and 35 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for inhibiting colon cancer cell migration *in vitro* and *in vitro* modulation of unregulated cell growth does not reasonably provide enablement for treating a wide variation of cancer. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make or use the invention commensurate in scope with these claims. The claims refer to "treating a medical condition" having chemopreventive activity with the compound



, based upon that, the applicant has not shown any *in vivo* result to convey this. In evaluating the enablement question, several factors are to be considered. Note *In re Wands*, 8 USPQ2d 1400 and *Ex parte Forman*, 230 USPQ 546. The factors include: 1) The nature of the invention, 2) the state of the prior art, 3) the predictability or lack thereof in the art, 4) the amount of direction or guidance present, 5) the presence or absence of working examples, 6) the breadth of the claims, 7) the relative skill of those skilled in the art and 8) the quantity of experimentation needed.

Art Unit: 1614

Response

Although, Applicant has in part addressed a section of the enablement rejection raised, the question still remain with regards to how one compound is capable of treating a very wide variation of cancer cells. Considering that every medication in other for it to kill the cells must contact the cell wall, this is not new in the art of cancer and treatment. In the art of cancer treatment, there is no one drug that is capable of treating cancer, especially, emphasis added a wide variation of cancers.

The affidavit submitted has been carefully, however, Applicant has still not shown with data how the skilled artisan would be able to practice treating various types of cancers with this drug successfully. Merely, stating that the drug is capable of treating because it acts on the cell wall is insufficient and does not give the monopoly asserted by the claim.

Applicant's arguments filed have been fully considered but they are not persuasive. For the reasons stated above. The rejection is hereby maintained and repeated.

Rejection (based on the composition to treat any type of cancer)**1) Nature of the invention.**

The nature of the invention is a method for treating a cancer in a subject comprises administering the instant pharmaceutical composition to a patient (mammal) in need thereof. As stated, however, claims 1, 5, 10, 20, 24, 29, 31 and 35 recite that any cancer is intended or a very wide variation of cancer.

2) State of the prior art and the predictability or lack thereof in the art.

The state of the prior art is that it involves screening *in vitro* and *in vivo* to determine which compounds exhibited the desired pharmacological activities (i.e. what compounds can treat which specific disease eg., colon, breast, lung etc). The existence of these obstacles establishes that the contemporary knowledge in the art would prevent one of ordinary skill in the art from accepting any therapeutic regimen on its face. The instant claimed invention is highly unpredictable as discussed below:

It is noted that the pharmaceutical art is unpredictable, requiring each embodiment to be individually assessed for physiological activity. *In re Fisher*, 427 F.2d 833, 166 USPQ 18 (CCPA 1970) indicates that the more unpredictable an area is, the more specific enablement is necessary in order to satisfy the statute. Further, their mode of action is often unknown or very unpredictable and administration of the drugs can be accompanied by undesirable side effects.

Thus, in the absence of a showing of correlation between the claimed compound as capable of treating medical condition which involves inhibiting colon cancer cell migration, modulation of unregulated cell growth *in vivo* as well as *in vitro*, one of skill in the art is unable to fully predict possible results from the administration of the compounds due to the unpredictability of the role of the claimed compound *in vivo*. Emphasis again added Gura (Science, 1997, 278:1041-1042) teaches that researchers face the problem of sifting through potential anticancer agents to find ones promising enough to make human clinical trials worthwhile and teach that since formal screening began in 1955, many thousands of drugs have shown activity in either cell or animal models but that only 39 have actually been shown to be useful for chemotherapy (p.

Art Unit: 1614

1041, see first and second para).

Also, more recently with regards to unpredictability, Johnson et al (British J. of Cancer 2001, 84(10) 1424-1431) teaches the use of 39 agents invivo activity in a particular histology in a tumor model did not closely relate to activity in the same human cancer. Because of the known unpredictability of the art, in the absence of experimental evidence, no one skilled in the art would accept the assertion that the claimed compound composition could be predictably used as an anti-cancer agent for any type of medical conditions which involves cancer as inferred by the claim and as contemplated by the specification. Further, the refractory nature of cancer to drugs is well known in the art

3) Quantity of experimentation needed to make or use the invention based on the content of the disclosure.

The quantity of experimentation needed is undue experimentation. One of ordinary skill in the art would first need to determine the type of cancer to be treated, and then determine what dosage of the claimed compounds would be suitable for said treatment and/or prevention without toxicity to the patient in need thereof. Guru et al taken with Johnson et al (cited above makes it clear that much more than routine experimentation is needed).

4) Level of predictability in the art.

The art pertaining to the treatment of a/any medical condition which involves cancer remain highly unpredictable. As disclosed above, there is no absolute predictability even in view of the seemingly high level of skill in the art. Firstly, the mode of action in vitro is different from the mode of action invivo. Even within the animal models, a compound effective against cancer or a disease associated with cancer with

a positive result in an animal model does not necessarily mean a positive result in humans. Cancer is a process that can take place in virtually any part of the body. There is a vast range of forms that it can take, causes for the problem, and biochemical pathways that mediate the cancer reaction. There is no common mechanism by which any, or even most, cancer arise.

5) Amount of direction and guidance provided by the inventor.

The amount of direction or guidance present is nowhere found in the specification. However, the gap between *in vitro* activity and *in vivo* utility is large enough to warrant thorough and compelling *in vivo* or clinical data.

6) Existence of working examples.

As discussed above, no working example is found in the current application. Applicant's omission of working examples does not enable one of ordinary skill in the art to treat all cancers encompassed by the instant invention.

7) Breadth of claims.

Claims 1, 5, 10, 20, 24, 29, 31 and 35 are extremely broad due to the recitation of all types and forms of cancer encompassed by the instant invention.

8) Level of ordinary skill in the art.

The level of ordinary skill in the art is high. Due to the unpredictability in the pharmaceutical art, it is noted that each embodiment of the invention is required to be individually assessed for physiological activity by *in vitro* and *in vivo* screening to determine which compounds exhibit the desired pharmacological activity and which diseases would benefit from this activity.

Hence, the specification fails to provide sufficient support of the broad use of the compounds of the claims for the treatment of any disease. As a result necessitating

one of ordinary skill in the art to perform an exhaustive search to determine which diseases can be treated by what compounds of the instant claims in order to practice the claimed invention.

II. Rejection based on treating any type of cancer with one compound.

1) The nature of the invention: The nature of the invention is treating all medical conditions associated with cancers which is extremely broad. For example pancreatic cancer, there is hardly a cure for this type of cancer. In view of the report Pancreatic cancer 2006, 90% of patients die within 12 months of diagnosis.

2) The state of the prior art: There are no examples shown in the specification on how to treat any cancer using the compound *invivo*. The state of the prior art is that it involves screening *in vitro* and *in vivo* to determine which cancer cell was inhibited by the compound. The existence of these obstacles establishes that the contemporary knowledge in the art would prevent one of ordinary skill in the art from accepting an *invitro* regime on its face. The instant claimed invention is highly unpredictable as discussed below:

It is noted that the pharmaceutical art is unpredictable, requiring each embodiment to be individually assessed for physiological activity. *In re Fisher*, 427 F.2d 833, 166 USPQ 18 (CCPA 1970) indicates that the more unpredictable an area is, the more specific enablement is necessary in order to satisfy the statute. Further, their mode of action is often unknown or very unpredictable and administration of the drugs can be accompanied by undesirable side effects.

Thus, in the absence of a showing of correlation between treating conditions of any-type of cancer, one of skill in the art is unable to fully predict possible results from the administration of the compound due to the unpredictability of the role of the diseases.

3) The predictability or lack thereof in the art: there is currently no completely effective therapy for treating a genus medical condition which are cancer, with one compound. Search for therapeutic agents useful for the treatment of cancer is ongoing. For example: The art pertaining to the treatment of cancer of any type of cancer remain highly unpredictable because there is a vast range of forms that it can take, causes for the problem, and biochemical pathways that mediate the disease.

4) The amount of direction or guidance present -The specification only provides examples to treating colon cell (invitro) and wounds (invitro). While the invitro examples may suffice as a preliminary step into the research, it no-where shows how one can extrapolate the date to an invivo testing. The examples shown will not enable one skilled in the art to treat any types of cancerous diseases.

5) Amount of direction and guidance provided by the inventor.

The amount of direction or guidance present found on pages 20-26 is not sufficient to enable one of skill in the art to treat all medical conditions that are cancers in vivo which embraces a myriad of conditions

6) Existence of working examples.

As discussed above, the working examples are found on pages 20-26 are insufficient for such a broad claim of treatment of all disease of angiogenesis. Applicant's limited working example does not enable one of ordinary skill in the art to treat all medical conditions which are cancer in the instant invention.

7) Breadth of claims.

Claim 1 is extremely broad due to the recitation of all types and forms of cancer encompassed by the instant invention.

8) Level of ordinary skill in the art.

The level of ordinary skill in the art is high. Due to the unpredictability in the pharmaceutical art, it is noted that each embodiment of the invention is required to be individually assessed for physiological activity by *in vitro* and *in vivo* screening to determine which cancers exhibit inhibitory effect of the instantly claimed compound.

Hence, the specification fails to provide sufficient support of the broad use of the compounds of the claims for the treatment of all cancers. As a result necessitating one of skill in the art to perform an exhaustive search to determine which diseases can be treated by the compound(s) of the instant claims in order to practice the claimed invention.

The above list is by no means complete, but demonstrates the extraordinary breadth of causes, mechanisms, and treatment (or lack thereof) for cancer.

I. Claims 1, 3, 11 and 15 together with dependent claims 5-6, 9, 17-24 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a written description rejection.

To satisfy the written description requirement, applicant must convey with reasonable clarity to one skilled in the art, as of the filing date that application was in

Art Unit: 1614

possession of the claimed invention. There is no description in the specification for treatment of a representative types of cancers listed in the above claims.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 32, 34-36 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for disrupting cells from , does not reasonably provide enablement for preventing the reorganization of the cytoskeleton unable to divide. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims.

Factors to be considered in determining whether a disclosure would require undue experimentation have been summarized in Ex parte Forman, 230 USPQ 546 (BPAI 1986) and reiterated by the Court of Appeals in In re Wands, 8 USPQ2nd 1400 at 1404 (CAFC 1988). The factors to be considered in determining whether undue experimentation is required include: (1) the quantity of experimentation necessary, (2) the amount or direction presented, (3) the presence or absence of working examples, (4) the nature of the invention, (5) the state of the prior art, (6) the relative skill of those in the art, (7) the predictability or unpredictability of the art, and (8) the breadth of the claims.

Art Unit: 1614

The Board also stated that although the level of skill in molecular biology is high, the results of experiments in genetic engineering are unpredictable. While all of these factors are considered, a sufficient amount for a prima facie case are discussed below.

Nature of the invention.

The nature of the invention is directed towards a method of disrupting and preventing the reorganization of cytoskeleton whereby an animal cell assumes a spherical configuration and unable to divide, move or invade by contacting the cell with a therapeutically effective amount of the compound of claim 32 or its enantiomer.

Preventing. As stated, prevention is to stop from ever occurring how does one prevent the cytoskeleton from dividing or moving. For example one component of a cytoskeleton the actin cytoskeleton one component of the internal scaffolding of a cell that helps it to maintain or alter its shape and also governs cell division and the transmission of external signals. A variety of cellular organelles are held in place by the actin cytoskeleton. In addition to providing support for the cell, the actin cytoskeleton is also involved in cellular motility and in the movement of vesicles within cells. Moreover, the actin cytoskeleton plays a crucial role in some types of immune response such as T-cell activation and phagocytosis.

State of the prior art and the predictability or lack thereof in the art.

There are no examples shown in the specification on how to disrupting and preventing the reorganization of cytoskeleton whereby an animal cell assumes a spherical configuration and unable to divide, move or invade by contacting the cell with a therapeutically effective amount of the compound of claim 30 or its enantiomer. Thus,

Art Unit: 1614

in the absence of a showing of correlation between treating conditions of any-type of cancer, one of skill in the art is unable to fully predict possible results from the administration of the compound due to the unpredictability of the role of the diseases.

Amount of direction and guidance provided by the inventor.

The amount of direction or guidance present found on pages 20-26 is not sufficient to enable one of skill in the art to disrupting and preventing the reorganization of cytoskeleton whereby an animal cell assumes a spherical configuration and unable to divide, move or invade by contacting the cell with a therapeutically effective amount of the compound of claim 30 or its enantiomer.

Existence of working examples.

As discussed above, working example is found on pages 60-62. However, Applicant has not shown how this prevention is done.

Breadth of claims.

Claims 32 is directed to prevention.

No claim is allowed.


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shirley V. Gembeh whose telephone number is 571-272-8504. The examiner can normally be reached on 8:30 -5:00, Monday- Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin Marschel can be reached on 571-272-0718. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1614

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

SVG
1/6/07


ARDIN H. MARSCHEL
SUPERVISORY PATENT EXAMINER